Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations

Sarah Horton 1
Maya H Buch 2
Paul Emery 2

1 Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds,
2 NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Abstract: Rheumatoid arthritis (RA) is a systemic inflammatory disease in which chronic inflammation leads to joint destruction and extra-articular complications. Early and effective inhibition of inflammation is critical in order to prevent the progressive joint damage that occurs rapidly after onset of the disease. In the past, treatment for this purpose was limited to conventional disease-modifying antirheumatic drugs (DMARDs), which were often suboptimal. Within the last decade however, the development of biologic therapies, targeted against cytokines and cells involved in the inflammatory process, has revolutionized the management of RA. Disease remission is now an achievable goal in newly diagnosed patients. Since the advent of the first tumor necrosis factor-α inhibitor in 1999, other biologics have proved necessary as individuals respond to varying degrees with different therapies. Several are now available for the treatment of patients with RA that remains active despite DMARD treatment. This article reviews the evidence, over the last decade, of the efficacy and safety of biologic therapies used in this context, and the recent clinical data supporting the use of biologic therapy earlier in the disease process as first-line therapy.

Keywords: rheumatoid arthritis, biologic therapy, tumor necrosis factor, abatacept, rituximab, tocilizumab, safety

Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting 1% of adult Western populations, and is the largest cause of treatable disability in the Western World. It is associated with considerable pain, stiffness, and swelling of joints. If not adequately controlled, it results in joint destruction, deformity, and disability. In addition, it is a systemic disorder; persistent systemic inflammation may lead to extra-articular manifestations, and also to increased cardiovascular morbidity and mortality.

The socio-economic impact is also significant. A study in 1989 demonstrated that, 10 years after diagnosis of RA, only half of patients were employed and 42% of patients considered themselves disabled. Since then, improved understanding of the disease has shaped clinical practice, with the current approach to treatment being based principally upon the paradigm that the level of inflammation over time determines damage. Studies have demonstrated that damage occurs early in the disease process, and that subclinical inflammation and associated joint damage can continue despite improvement in patients’ symptoms with treatment. Hence, the aim of treatment of RA has advanced from symptom control to early and optimal control of inflammation, with use of immunosuppressive disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX).
Comparison of treatment strategies in early RA has confirmed that tight control of inflammatory disease activity offers improved outcomes for patients. The TICORA study compared routine treatment (DMARD treatment and three-monthly assessment) to intensive management involving monthly assessment and escalation of DMARD treatment in the presence of even low-level disease activity, according to a protocol. A similar comparison of three-monthly versus monthly assessment was employed in the CAMERA study, in which treatment with MTX was increased, or another DMARD was added as necessary to meet targets of disease control.

For a number of patients however, MTX and other conventional DMARDs are ineffective at achieving suppression of disease activity and preventing permanent joint damage. This need for alternative, superior treatment options has led to the development of biologic therapies, targeted against cells and cytokines known to play a role in the pathogenesis of RA (Figure 1). In clinical practice, biologic therapies are licensed for use in patients with moderate to severely active RA who have not responded to DMARDs. This article reviews the evidence supporting their use in these circumstances and the emerging evidence for use outside this remit in patients with early RA who may not have previously received DMARD treatment.

Assessing efficacy of biologics

International standards for assessment of disease activity in RA allow comparison of response to treatment across studies (Table 1). When a number of outcome measures of disease activity were assessed using expert opinion and analysis of placebo-controlled trial data, 20% improvement in the American College of Rheumatology response criteria (ACR20) proved reliable at discriminating active treatments from placebo effects. This is commonly used as the primary outcome measure in randomized controlled trials of RA treatment, including many of the trials discussed in this review. However, it is of no use for measuring the status of disease activity in the individual patient in clinic, unlike the Disease Activity Score (DAS), a continuous variable that relates to disease state and is useful in clinical practice.

**TNF inhibition**

The first inhibitor of the cytokine tumor necrosis factor-α (TNF-α), infliximab, was launched over 10 years ago, initially for use in Crohn’s disease. Since then, infliximab and others have been approved for use in rheumatoid disease. Infliximab, adalimumab, and etanercept are blockers of TNF that have been used in clinical practice for several years, while certolizumab and golimumab have recently been developed and approved (Table 2). Clinical trials demonstrating their efficacy are discussed below.

**Infliximab**

An initial dose-ranging study of infliximab demonstrated reduced immunogenicity and better efficacy when administered with MTX, and it was licensed for use with

---

**Table 1**

<table>
<thead>
<tr>
<th>Cell surface proteins on lymphocytes</th>
<th>Cytokines</th>
</tr>
</thead>
<tbody>
<tr>
<td>T lymphocytes (CTLA 4)</td>
<td>Tumor necrosis factor-α</td>
</tr>
<tr>
<td>B lymphocytes (CD20)</td>
<td>Interleukin-6</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Infliximab</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Adalimumab</td>
</tr>
<tr>
<td></td>
<td>Etanercept</td>
</tr>
<tr>
<td></td>
<td>Certolizumab</td>
</tr>
<tr>
<td></td>
<td>Golimumab*</td>
</tr>
<tr>
<td></td>
<td>Tocilizumab</td>
</tr>
</tbody>
</table>

**Figure 1** Targets of current biological therapies for RA.

**Note:** *Developed and assessed in clinical trials, but not yet widely available.

**Abbreviations:** CTLA 4, cytotoxic T-lymphocyte antigen 4; CD, cluster of differentiation.
MTX in 1999. The ATTRACT study went on to assess the efficacy of infliximab with MTX in patients who had active RA despite at least three months of treatment with MTX. Patients were randomized to placebo or one of four treatment regimens: infliximab 3 mg/kg every 4 or 8 weeks and 10 mg/kg every 4 or 8 weeks. Disease duration ranged between 0.5 and 49.9 years, but was matched across treatment groups, with the median duration being 7.2–9.0 years across the groups. At 30 weeks, superior clinical response, assessed by the proportion of patients achieving ACR20 and ACR50, was seen in all groups receiving infliximab compared to placebo (Table 3). The study was continued to 54 weeks. Response with infliximab plus MTX was sustained, and superiority to placebo plus MTX remained significant. As efficacy was comparable between infliximab groups but side-effects were more frequent with higher doses, 3 mg/kg was chosen as the licensed dose. After this year, treatment was unblinded and patients could continue their allocated treatment over a further one year. Lower numbers of patients in the placebo group (28 compared to 55–64 in the infliximab plus MTX groups) may be accounted for by their high rate of withdrawal due to lack of efficacy in the first year (36%). Again, clinical response was maintained, as illustrated by similar ACR20, ACR50 and ACR70 responses.

Progression in joint damage at one year was compared between groups using the mean change in the total modified Sharp score from baseline. The mean change in total score in the MTX controls was 7.0, compared to a mean change ranging from −0.7 to 1.6 in infliximab-treated groups (P < 0.001), with the mean improvement of 0.7 seen in patients receiving the highest dose of infliximab. Even in patients who did not clinically respond to treatment (ie, did not meet ACR20 criteria), infliximab had a beneficial effect on radiographic progression; mean change in total score in the MTX nonresponders was 7.2 compared to a mean of 0.2–2.6 in infliximab nonresponders (P ≤ 0.002). In a sub-analysis of patients with early disease (less than three years disease duration), even greater differences were seen with the addition of infliximab. Mean changes in total score were 9.1 in MTX controls compared to −1.1 to 0.6 with infliximab and MTX.

Table 1 Outcome measures used in intervention studies in RA

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Method of assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite measures of disease activity:</td>
<td></td>
</tr>
<tr>
<td>American College of Rheumatology (ACR) response criteria:</td>
<td>A 20%, 50% or 70% improvement in the following measures of disease:</td>
</tr>
<tr>
<td>• ACR20</td>
<td>• number of tender joints</td>
</tr>
<tr>
<td>• ACR50</td>
<td>• number of swollen joints</td>
</tr>
<tr>
<td>• ACR70</td>
<td>• at least three out five further criteria: patient’s assessment of pain, global health, or physical function; physician assessment of global health or a laboratory marker of inflammation (CRP or ESR).*</td>
</tr>
<tr>
<td>Disease activity score (DAS)</td>
<td>Calculated using a mathematical formula comprising:</td>
</tr>
<tr>
<td></td>
<td>• number of swollen joints (out of 28 specified joints in the case of DAS28)</td>
</tr>
<tr>
<td></td>
<td>• number of tender joints (out of 28)</td>
</tr>
<tr>
<td></td>
<td>• patient self-assessment of global health (on a visual analog scale)</td>
</tr>
<tr>
<td></td>
<td>• laboratory markers (CRP or ESR)</td>
</tr>
<tr>
<td></td>
<td>A DAS28 score of 5.1 or more is classed as high disease activity; low disease activity is 3.2 or less, and clinical remission is less than 2.6.</td>
</tr>
<tr>
<td>Patient outcomes:</td>
<td></td>
</tr>
<tr>
<td>Health-related quality of life, Short form-36 (SF-36)</td>
<td>A self-assessment questionnaire measuring eight aspects of mental and physical well-being, summarized in the mental component summary (MCS) and physical component summary (PCS), judged on a scale of 0 to 100, where 0 is the worst and 100 is the best outcome. The minimal improvement which is accepted as meaningful is a decrease of at least 3 units.*</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Health assessment questionnaire disability index (HAQ-DI)</td>
<td>A self-assessment questionnaire of 8 aspects of physical disability, giving a score of 0 to 3, where 0 is no disability and 3 is completely disabled. The minimal improvement which is accepted as meaningful is a decrease of 0.22 or more.*</td>
</tr>
<tr>
<td>Radiological outcomes:</td>
<td></td>
</tr>
<tr>
<td>Sharp score (and modifications of it)</td>
<td>Grading of the radiographic appearance of joints according to the degree of narrowing of the joint space and the severity of bone erosions.*</td>
</tr>
</tbody>
</table>

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
The ASPIRE study similarly compared MTX alone to combination with infliximab, but included only patients with RA of less than three years duration who were MTX-naive. The majority of patients had not had prior exposure to any DMARDs. As expected, compared to the ATTRACT study of MTX-resistant patients, higher ACR response rates were seen across all treatment groups (Table 3). Despite the higher response rates in this study with MTX alone, significantly higher proportions of patients on infliximab in combination with MTX achieved the superior response levels (ACR50 and ACR70). The addition of infliximab also significantly decreased the progression of joint damage, assessed using the modified Sharp score; from the median increase of 0.4 with MTX alone to a median change of 0.0 seen in infliximab treatment groups ($P < 0.001$).

The BeSt study compared four treatment strategies in early RA: MTX alone, changing to alternative DMARDs if response inadequate; MTX alone, adding other DMARDs in combination if response inadequate; combination DMARD therapy initially with high-dose corticosteroids; and MTX with the biologic agent infliximab initially. More rapid clinical improvement was achieved when a combination of DMARDs or MTX with infliximab was used as a first line, with less progression of joint damage seen on radiographs. In cases where disease remained effectively suppressed, drug therapies (preferentially corticosteroids or infliximab in the first instance) were tapered and withdrawn. This was most successful in the group initially treated with infliximab combination therapy; 53% of patients were on just one drug for disease control at the end of the two-year study (compared to 31%–36% in other groups).

### Table 2: TNF inhibitors used in RA

<table>
<thead>
<tr>
<th>TNF inhibitor</th>
<th>Molecular structure</th>
<th>Administration</th>
<th>Randomized controlled trials (double-blind, unless otherwise stated)</th>
</tr>
</thead>
</table>
| Infliximab    | Chimeric monoclonal antibody to TNF; human and mouse components. | - Dose  
- Route  
- Frequency  
- 3 or 5 mg/kg  
- Intravenous  
- At 0, 2, and 6 weeks then every 2 months  
- Concomitant MTX is necessary to decrease immunogenicity. | ATTRACT$^{11,12}$  
Early RA and MTX-naïve: ASPIRe$^{13}$  
Early RA: BeSt$^{14}$ (single-blind) |
| Adalimumab    | Fully human monoclonal antibody to TNF. | - 40 mg  
- Subcutaneous  
- Every 2 weeks | ARMADA$^{15}$  
vander Putte et al$^{16}$  
Early RA and MTX-naïve: PREMIER$^{17}$  
PROWD$^{18}$  
Weinblatt et al$^{19}$  
Moreland et al$^{20}$  
TEMO$^{21}$  
Early RA and MTX-naïve: COMET$^{22}$  
Bathon et al$^{23}$  
RAPID 1$^{24}$  
RAPID 2$^{25}$  
FAST4WARD$^{26}$ |
| Etanercept    | Fusion protein of the soluble TNF receptor, linked to the constant fragment (Fc) of immunoglobulin. | - 50 mg  
- Subcutaneous  
- Every week (or 25 mg twice weekly) | Early RA and MTX-naïve:  
Moreland et al$^{20}$  
van der Putte et al$^{16}$  
Early RA and MTX-naïve:  
PREMIER$^{17}$  
PROWD$^{18}$  
Weinblatt et al$^{19}$  
Moreland et al$^{20}$  
TEMO$^{21}$  
Early RA and MTX-naïve:  
COMET$^{22}$  
Bathon et al$^{23}$  
RAPID 1$^{24}$  
RAPID 2$^{25}$  
FAST4WARD$^{26}$ |
| Certolizumab  | Antigen-binding fragment (Fab) of human anti-TNF antibody bound to polyethylene glycol, as opposed to the Fc fragment present in other monoclonal antibodies and anti-TNF drugs. Developed with lack of the Fc fragment, with the intention of increasing its half-life and reducing immunogenicity. | - 400 mg  
- Subcutaneous  
- At 0, 2, and 4 weeks then every 4 weeks (or 200 mg every 2 weeks) | RAPiD 1$^{24}$  
RAPiD 2$^{25}$  
FAST4WARD$^{26}$ |
| Golimumab     | Fully human monoclonal antibody to TNF. | - 50 mg  
- Subcutaneous  
- Every 4 weeks | GO-FORWARD$^{27}$  
Early RA and MTX-naïve:  
GO-BEFORE$^{28}$  
Previous Anti-TNF Treatment: GO-AFTER$^{29}$ |
Quinn et al attempted to induce clinical remission in very early RA (DMARD-naïve patients with less than one year of symptoms) in a small number of patients with poor prognostic features of disease such as positive rheumatoid factor. Thirty-two patients were treated with MTX and randomly assigned to receive either placebo or infliximab for one year. The primary outcome of the study was achieved (a difference between the groups in reduction of synovitis on magnetic resonance imaging at 14 weeks). Improvement in disease control, assessed by DAS28, was more rapid in the infliximab group; at 14 weeks, median DAS28 was significantly lower compared with the placebo group. But at 2 years (one year after stopping infliximab), although median DAS28 was lower in infliximab-treated patients and within the remission range, there was no significant difference compared to placebo. There was a significant difference between the groups at 2 years however: in physical function, improvement with adalimumab treatment was maintained.

Adalimumab

Results of the ARMADA trial were published in 2003, showing the efficacy of adalimumab in combination with MTX. Similar to the ATTRACT study for infliximab, patients had a range of disease duration (on average approximately 12 years) and had active disease despite at least 6 months of MTX treatment. At 24 weeks, at a dose of 40 mg every two weeks (the dose used in current clinical practice), patients had significantly greater clinical responses at ACR20, ACR50, and ACR 70 levels (Table 4). Patients reported greater improvement in physical function as assessed by the 0–3 scale of the HAQ score; mean improvement of 0.62 with adalimumab and MTX, compared to 0.27 with MTX alone ($P < 0.001$). Long-term efficacy data is available after a 4-year open-label extension study in which all patients received adalimumab in combination with MTX. The proportion of patients still receiving adalimumab at 4 years was 62%; adalimumab was stopped in 8% of patients due to lack of efficacy. Comparison between data at 6 months and 4 years, for patients in the original adalimumab treatment groups who continued on treatment, showed that clinical response with adalimumab treatment was maintained.

Keystone et al assessed the effect of adalimumab plus MTX on radiographic progression over one year in a randomized controlled trial of MTX nonresponders. Patients treated with adalimumab and MTX had a smaller mean change in modified total Sharp score compared to patients on MTX and placebo (0.1 vs 2.7; $P < 0.001$).

Unlike infliximab, adalimumab has been shown to be safe and effective when used as monotherapy. This was confirmed by van der Putte et al in patients who had, on average, a disease duration of 11 years, and had failed previous DMARD treatment (the majority of patients had failed at least three different DMARDs). The proportion of patients achieving an ACR20 response was significantly higher in the adalimumab group compared to the placebo group (46% vs 19%;

Table 3 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination infliximab and methotrexate compared to methotrexate alone

<table>
<thead>
<tr>
<th>ATTRACT</th>
<th>ASPIRE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX + INF</td>
<td>MTX + INF</td>
</tr>
<tr>
<td>MTX + INF</td>
<td>MTX + INF</td>
</tr>
</tbody>
</table>

At 30 wks (%):  
ACR 20: 20% 50% 53% 52% 58%  
ACR 50: 5% 27% 29% 31% 26%  
ACR 70: 0% 8% 11% 18% 11%  

At 54 wks (%):  
ACR 20: 17% 42% 48% 59% 59% 54% 62% 66%  
ACR 50: 8% 21% 34% 39% 38% 32% 46% 50%  
ACR 70: 2% 10% 17% 25% 19% 21% 33% 37%  

Note: $P < 0.001$ compared to placebo.  
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate; INF, infliximab.
Table 4 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination adalimumab and methotrexate (ARMADA)\textsuperscript{15} and adalimumab monotherapy (van der Putte)\textsuperscript{16}

<table>
<thead>
<tr>
<th>ARMADA\textsuperscript{15}</th>
<th>van der Putte et al\textsuperscript{16}</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX + placebo</td>
<td>Placebo</td>
</tr>
<tr>
<td>n = 67</td>
<td>n = 113</td>
</tr>
<tr>
<td>MTX + adalimumab 40 mg</td>
<td>Adalimumab</td>
</tr>
<tr>
<td>2 weekly</td>
<td>40 mg</td>
</tr>
<tr>
<td>n = 62</td>
<td>2 weekly</td>
</tr>
</tbody>
</table>

At 24–26 wks (%):

- ACR 20: 15 vs 67\textsuperscript{a} 19 vs 46\textsuperscript{a}
- ACR 50: 8 vs 55\textsuperscript{b} 8 vs 22
- ACR 70: 5 vs 27\textsuperscript{b} 2 vs 12

\textsuperscript{Note:} \textsuperscript{a}P < 0.001 compared to placebo.

\textsuperscript{Abbreviations:} ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.

This has importance for patients who are unable to take MTX, either because of intolerance to its side-effects or due to a contraindication. However, as superior efficacy is achieved with combination treatment, MTX should be used when possible.

The PREMIER study investigated patients with early RA (disease duration up to 3 years) and poor prognostic disease (rheumatoid factor positive or at least 1 joint erosion).\textsuperscript{17} Patients were excluded if they had received specified DMARDs including MTX. Patients were randomized to receive adalimumab in combination with MTX, adalimumab monotherapy, or MTX monotherapy. Of patients in the combination therapy arm, 62% achieved the primary endpoint of an ACR50 response, which was significantly greater in comparison to adalimumab monotherapy (46%) and MTX monotherapy (41%) (P < 0.001 for both comparisons). The rate of remission (DAS28 < 2.6) at 2 years was 49% in patients on combination therapy, twice that seen in the other treatment arms. At 2 years, the mean change in modified total Sharp score with the combination treatment was 1.9 compared to 10.4 with MTX alone (P < 0.001); and HAQ Disability Index (DI) improved by the minimal clinically meaningful difference in 72% of patients on combination therapy compared to 58% and 63% in adalimumab and MTX monotherapy groups respectively (P < 0.05). Further analysis to determine the relationship between radiographic progression and clinical response demonstrated that significantly less radiographic progression was achieved in patients on combination therapy compared to MTX monotherapy across all clinical outcomes, including patients who showed poor clinical response (patients not meeting the ACR20 response criteria).\textsuperscript{37}

In a sub-analysis of patients in the PREMIER study, effect on quality of life was assessed, using the SF-36 health survey, and compared to a sample of the general United States population (from a national survey in 1998).\textsuperscript{38} As expected, baseline scores for the physical component summary (PCS) and mental component summary (MCS) were higher in the US population compared to the RA group. At 2 years, the PCS for those receiving combination therapy increased to a level similar to that of the general population (47.8 vs 49.4; P = 0.08). For those receiving MTX monotherapy, the score increased but remained significantly lower than the general population (44.4 vs 49.4; P < 0.0001). This is impressive, considering that these were patients selected on the basis of indicators of poor prognosis.

In the PROWD study, MTX-naïve patients with early RA (duration up to 2 years) who had self-reported work impairment were randomized to adalimumab and MTX, or placebo and MTX.\textsuperscript{19} There was no difference in the primary outcome (job loss from any cause and/or imminent job loss after week 16): 16% of patients on adalimumab and MTX compared to 27% of patients on MTX monotherapy (P = 0.092). There was a statistical difference however, if numbers over the full 56-week study period were taken: 19% compared to 40% respectively (P = 0.005). The authors point out that this may be due to the fact that more patients in the placebo group dropped out after week 16 (25 patients) compared to the adalimumab-treated group (15 patients).

**Etanercept**

Two randomized controlled trials published in 1999 showed the efficacy of etanercept. One study demonstrated the efficacy of etanercept in combination with MTX,\textsuperscript{19} and the other etanercept monotherapy.\textsuperscript{20} ACR20 was achieved in 71% of patients on etanercept and MTX combination therapy compared to 27% of controls (P < 0.001), and in 59% on etanercept monotherapy compared to 11% of controls (P < 0.001) (Table 5). Study subjects were similar: mean disease durations were 13 years and 12 years respectively, and both studies required nonresponse to previous DMARDs (MTX in the study by Weinblatt et al and one out of four specified DMARDs, including MTX, in the study by Moreland et al).\textsuperscript{19,20}

The TEMPO trial went on to compare three treatment groups in a double-blind controlled design: etanercept and MTX in combination, etanercept monotherapy, and MTX monotherapy.\textsuperscript{21} Patients also had established RA, but mean disease duration was lower (6.8 years), and they were required to have had lack of response to DMARD therapy but not...
MTX. This explains the higher response rates seen in the MTX group. In this patient cohort, a significantly better clinical response rate over MTX monotherapy was seen with etanercept and MTX at ACR50 and ACR70 levels, but no significant difference was seen with etanercept monotherapy (Table 5). However, radiographic progression was significantly less; at 1 year the mean change in total Sharp score for etanercept in combination with MTX, etanercept monotherapy, and MTX monotherapy was −0.54, 0.52, and 2.80 respectively (P < 0.0001 for combination therapy vs MTX, and P = 0.0469 for etanercept monotherapy vs MTX). Improvement in patients’ self-reported physical functioning, HAQ DI, was significantly greater in the combination group, but was not significantly different between etanercept monotherapy and MTX monotherapy (improvements of 1.0, 0.7, and 0.65 respectively). Quality of life was assessed using the European Quality of Life Health Status Visual Analog Scale, and superior improvements in quality of life were reported by patients on combination treatment.39

Etanercept treatment was also assessed in MTX-naïve patients with early RA: the COMET study and a study by Bathon et al.22,23 COMET assessed etanercept in combination with MTX, and Bathon et al assessed etanercept monotherapy. COMET was different to previous trials in early arthritis, as remission was used for the first time as the study endpoint (DAS28 < 2.6), as opposed to using ACR response criteria. At one year, the proportion of patients who achieved DAS28 remission was greater with etanercept and MTX than with MTX alone (50% compared to 28%; P < 0.0001). This benefit was sustained at 2 years; 57% of patients who continued on combination therapy achieved DAS28 remission, compared to 35% of patients remaining on MTX (P = 0.002).40 This remission rate is greater than that seen in studies of MTX-naïve patients with longer disease duration, such as the TEMPO trial, in which the DAS28 remission rate was 42% at 2 years with combination treatment. Bathon et al showed etanercept monotherapy was more effective than MTX in the first 6 months, with greater percentages of patients achieving ACR20, ACR50 and ACR70 (P < 0.05). At 2 years, there was a significant difference in the proportion of patients achieving ACR20 (72% vs 59% of MTX controls; P = 0.005), but no significant difference at ACR50 and ACR70 levels.41 Patients completing the study by Bathon et al entered an open-label extension study of etanercept monotherapy, extending treatment to 5 years.42 Efficacy was maintained for patients who remained on etanercept from the original treatment group, with 68% fulfilling ACR20 criteria at 5 years.

Both studies also assessed radiographic progression. In the COMET study, no progression (defined as a change in modified total Sharp score of 0.5 or less) was seen in 80% of patients on etanercept and MTX, compared to 59% on MTX alone (P < 0.0001). Similarly, nonprogression at 2 years was demonstrated more frequently with etanercept monotherapy than with MTX by Bathon et al (63% compared to 51%; P = 0.017). In terms of patient outcomes, COMET showed a significant difference in improvement in HAQ DI score over 1 year between patients receiving etanercept with MTX and MTX alone (improvements of 1.0 and 0.7 respectively; P < 0.001). Patients receiving etanercept and MTX also experienced benefits in terms of work stability; of patients in full or part-time work at baseline, 9% had stopped work at least once during the study, compared to 24% on MTX.

### Table 5 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination etanercept and methotrexate and etanercept monotherapy

<table>
<thead>
<tr>
<th></th>
<th>Weinblatt et al22</th>
<th>Moreland et al23</th>
<th>TEMPO21</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX + placebo n = 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX + etanercept 25 mg twice weekly n = 59</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td>27</td>
<td>11</td>
<td>75</td>
</tr>
<tr>
<td>ACR 50</td>
<td>3</td>
<td>5</td>
<td>48</td>
</tr>
<tr>
<td>ACR 70</td>
<td>0</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>At 24–26 wks (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 52 wks (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td></td>
<td>75</td>
<td>43</td>
</tr>
<tr>
<td>ACR 50</td>
<td></td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>ACR 70</td>
<td></td>
<td>19</td>
<td>43</td>
</tr>
</tbody>
</table>

Note: *P < 0.001* compared to placebo.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.

---

*Note:* Similar to previous trials in early arthritis, as remission was used for the first time as the study endpoint (DAS28 < 2.6), as opposed to using ACR response criteria.

*At one year, the proportion of patients who achieved DAS28 remission was greater with etanercept and MTX than with MTX alone (50% compared to 28%; P < 0.0001).* This benefit was sustained at 2 years; 57% of patients who continued on combination therapy achieved DAS28 remission, compared to 35% of patients remaining on MTX (P = 0.002). This remission rate is greater than that seen in studies of MTX-naive patients with longer disease duration, such as the TEMPO trial, in which the DAS28 remission rate was 42% at 2 years with combination treatment. Bathon et al showed etanercept monotherapy was more effective than MTX in the first 6 months, with greater percentages of patients achieving ACR20, ACR50 and ACR70 (P < 0.05). At 2 years, there was a significant difference in the proportion of patients achieving ACR20 (72% vs 59% of MTX controls; P = 0.005), but no significant difference at ACR50 and ACR70 levels. Patients completing the study by Bathon et al entered an open-label extension study of etanercept monotherapy, extending treatment to 5 years. Efficacy was maintained for patients who remained on etanercept from the original treatment group, with 68% fulfilling ACR20 criteria at 5 years.

Both studies also assessed radiographic progression. In the COMET study, no progression (defined as a change in modified total Sharp score of 0.5 or less) was seen in 80% of patients on etanercept and MTX, compared to 59% on MTX alone (P < 0.0001). Similarly, nonprogression at 2 years was demonstrated more frequently with etanercept monotherapy than with MTX by Bathon et al (63% compared to 51%; P = 0.017). In terms of patient outcomes, COMET showed a significant difference in improvement in HAQ DI score over 1 year between patients receiving etanercept with MTX and MTX alone (improvements of 1.0 and 0.7 respectively; P < 0.001). Patients receiving etanercept and MTX also experienced benefits in terms of work stability; of patients in full or part-time work at baseline, 9% had stopped work at least once during the study, compared to 24% on MTX.
alone. Bathon et al also showed a difference in improvement in HAQ DI after 2 years; 55% of etanercept patients had improved by at least 0.5 units, compared to 37% of MTX patients ($P < 0.001$).

**Certolizumab pegol**

Results showing efficacy in rheumatoid arthritis have been reported in patients with RA resistant to 6 months of MTX (RAPID 1 and 2),\(^{24,25}\) and patients with RA resistant to 6 months of MTX or other DMARDs (FAST4WARD).\(^{26}\) Approximately 80% of patients in the FAST4WARD study had previously been treated with MTX and, on average, had failed two DMARDs. RAPID 1 and 2 showed efficacy of two different preparations of certolizumab (lyophilized and liquid) in combination with MTX, whereas FAST4WARD used certolizumab as monotherapy. Success in achieving clinical response compared to placebo is shown in Table 6. RAPID 1 and RAPID 2 produced similar response rates with the different preparations. Therefore, only data from RAPID 1 is presented here, for simplicity. Clinical responses were maintained to week 52 in RAPID 1 and 2.

Improvement in physical function was significantly greater with certolizumab used in combination with MTX, and as monotherapy, compared to control groups. Mean improvement in HAQ DI was 0.6 at 52 weeks with combination therapy in RAPID 1, and 0.36 at 24 weeks with monotherapy in FAST4WARD ($P < 0.001$ against placebo in both studies). With combination therapy in RAPID 1, inhibition of radiographic progression was significantly greater than MTX alone ($P < 0.001$), but was not assessed in FAST4WARD.

**Golimumab**

Efficacy in combination with MTX and as monotherapy has been assessed in patients who are MTX-naïve (GO-BEFORE),\(^{28}\) and patients with active RA despite MTX treatment (GO-FORWARD).\(^{27}\) Results in terms of ACR response are shown in Table 7.

Golimumab is unique amongst the anti-TNF therapies in that there is randomized controlled trial evidence for its efficacy in patients who have previously received anti-TNF therapy. In the GO-AFTER study, 58% of patients had received previous anti-TNF treatment that was stopped due to lack of efficacy, and 34% of patients had received more than one anti-TNF in the past.\(^{29}\) Golimumab was given with or without at least one DMARD. Approximately two thirds of patients were taking concomitant MTX. A statistically significant difference was seen compared to placebo in the percentage of patients achieving ACR20 (34% vs 17%) and ACR50 responses (18% vs 5%) ($P < 0.001$ for both levels of response). There was also a difference in improvement in HAQ DI; mean improvement was 0.3 with golimumab, but 0.0 in controls ($P < 0.001$).

### Inhibition of T cell activation: abatacept

For T cell activation, in addition to binding to antigen, a co-stimulatory signal is also necessary. This is produced by the binding of CD28 molecules on the T cell surface to CD80/CD86 molecules on the surface of an antigen-presenting cell. T cells are capable of expressing cytotoxic T-lymphocyte antigen 4 (CTLA 4), which binds to CD80/CD86 more readily than CD28, thereby preventing this second process required for T cell activation. Abatacept is a recombinant protein consisting of the extracellular domain of CTLA 4 and human immunoglobulin; therefore, it inhibits T cell activation.\(^{43}\) It is given intravenously at a dose of 10 mg/kg every 4 weeks.

Abatacept has been assessed in combination with DMARD therapy (usually MTX) in randomized controlled trials of patients with established RA which is active despite MTX (AIM and Kremer et al),\(^{44,45}\) and despite previous anti-TNF treatment (ATTAIN)\(^{46}\). All demonstrated higher

### Table 6 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination certolizumab and methotrexate (RAPID 1)\(^{24}\) and certolizumab monotherapy (FAST4WARD)\(^{26}\)

<table>
<thead>
<tr>
<th></th>
<th>RAPID 1(^{24})</th>
<th>FAST4WARD(^{26})</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MTX + placebo n = 199</td>
<td>MTX + certolizumab 200 mg 2 weekly n = 393</td>
</tr>
<tr>
<td>At 24 wks (%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td>14</td>
<td>59(^a)</td>
</tr>
<tr>
<td>ACR 50</td>
<td>8</td>
<td>37(^a)</td>
</tr>
<tr>
<td>ACR 70</td>
<td>3</td>
<td>21(^a)</td>
</tr>
</tbody>
</table>

Notes: $P < 0.001$ compared to placebo.

**Abbreviations:** ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.
rates of clinical improvement and improvement in physical function with abatacept plus DMARD in comparison to DMARD alone (Table 8). In all three studies, significantly more patients in abatacept groups achieved clinically meaningful improvement in HAQ scores ($P < 0.001$). Abatacept has also been shown to improve health-related quality of life. For example, in the ATTAIN study, improvement in PCS and MCS scores of the SF-36 was greater than improvement in the control group at levels of significance of $P < 0.001$ and $P < 0.01$ respectively. The AIM study also assessed radiographic change, showing approximately 50% reduction in the progression of radiographic damage when abatacept was added to DMARD treatment; median change in total Genenant-modified Sharp score from baseline was 0.25 with abatacept plus DMARD therapy, compared to 0.53 with DMARD therapy alone ($P = 0.012$).

Patients completing these trials were eligible to receive 10 mg/kg abatacept with DMARD in open-label extension studies. In all three studies, the ACR response rates achieved in the original abatacept groups were maintained at the end of the study periods, in the patients who remained on abatacept. The rate of discontinuation due to lack of efficacy was 2% over the 1-year extension period of the AIM trial, $47$ 11% over the 4-year extension by Kremer et al $48$ and 16% over 18 months after the ATTAIN trial (patients who had previously received anti-TNF). $49$ Radiographic progression in the original abatacept group of the AIM trial was significantly slower in the second year of treatment compared to the first, suggesting an increasing effect of abatacept on structural damage in year 2. $43$

Abatacept in combination with MTX was assessed in MTX-naïve patients with early RA (disease duration up to 2 years) and poor prognostic factors (seropositive for rheumatoid factor and/or anti-CCP), and presence of

Table 7 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination golimumab and methotrexate and golimumab monotherapy compared to methotrexate monotherapy

<table>
<thead>
<tr>
<th>GO-BEFORE$^{33}$</th>
<th>GO-FORWARD$^{37}$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MTX + placebo</strong></td>
<td><strong>MTX + placebo</strong></td>
</tr>
<tr>
<td>n = 160</td>
<td>n = 133</td>
</tr>
<tr>
<td>Golimumab 100 mg 4 weekly</td>
<td>Golimumab 100 mg 4 weekly</td>
</tr>
<tr>
<td>n = 159</td>
<td>n = 133</td>
</tr>
<tr>
<td>MTX + abatacept 50 mg 4 weekly</td>
<td>MTX + abatacept 50 mg 4 weekly</td>
</tr>
<tr>
<td>n = 159</td>
<td>n = 89</td>
</tr>
</tbody>
</table>

At 24 wks (%):

<table>
<thead>
<tr>
<th>ACR 20</th>
<th>ACR 50</th>
<th>ACR 70</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>29</td>
<td>5</td>
</tr>
<tr>
<td>52</td>
<td>33</td>
<td>11$^a$</td>
</tr>
<tr>
<td>$62^a$</td>
<td>$40^a$</td>
<td>$20^a$</td>
</tr>
</tbody>
</table>

At 6 months (%):

<table>
<thead>
<tr>
<th>ACR 20</th>
<th>ACR 50</th>
<th>ACR 70</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>73$^a$</td>
<td>$48^a$</td>
<td>29$^a$</td>
</tr>
</tbody>
</table>

At 12 months (%):

<table>
<thead>
<tr>
<th>ACR 20</th>
<th>ACR 50</th>
<th>ACR 70</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>73$^a$</td>
<td>$48^a$</td>
<td>29$^a$</td>
</tr>
</tbody>
</table>

Notes: $^aP < 0.001$ compared to placebo group; $^bP < 0.05$ compared to placebo group.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.

Table 8 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination abatacept and methotrexate or alternative DMARD compared to DMARD alone

<table>
<thead>
<tr>
<th>AIM$^{44}$</th>
<th>Kremer et al$^{45}$</th>
<th>ATTAIN$^{46}$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MTX + placebo</strong></td>
<td><strong>MTX + placebo</strong></td>
<td><strong>DMARD + placebo</strong></td>
</tr>
<tr>
<td>n = 219</td>
<td>n = 119</td>
<td>n = 133</td>
</tr>
<tr>
<td>MTX + abatacept 10 mg/kg 4 weekly</td>
<td>MTX + abatacept 10 mg/kg 4 weekly</td>
<td>n = 433</td>
</tr>
<tr>
<td>n = 433</td>
<td>n = 115</td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td>ACR 50</td>
<td>ACR 70</td>
</tr>
<tr>
<td>40</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>73$^a$</td>
<td>48$^a$</td>
<td>29$^a$</td>
</tr>
<tr>
<td>At 6 months (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 12 months (%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: $^aP < 0.001$ compared to placebo group.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate.
radiographic erosions.\textsuperscript{50} Primary endpoints were remission (DAS28 < 2.6) and Genant-modified total Sharp score at 1 year. DAS28 remission was achieved in 42% of patients in the abatacept and MTX group, compared to 23% receiving MTX alone ($P < 0.001$). There was also a significant slowing of radiographic progression (mean change in total score 0.63 \textit{vs} 1.06; $P = 0.040$). Results are comparable to anti-TNF in early RA; for example, the COMET study of etanercept. This is particularly impressive, considering that patients were selected based on the basis of poor prognostic factors (90% of patients were anti-CCP positive).

Unlike other biologic treatments, the efficacy of abatacept in undifferentiated arthritis has been assessed.\textsuperscript{51} Patients were anti-CCP positive with at least two swollen and tender joints, and therefore highly likely to develop RA, but did not yet fulfil the criteria for the 1987 definition of RA by the American College of Rheumatology.\textsuperscript{52} They were randomized to abatacept or placebo treatment for 6 months. At one year (6 months after treatment was discontinued), 46% of abatacept-treated versus 67% of placebo-treated patients developed RA (95% confidence interval for the difference between the groups: $-47\%$ to 7%). Abatacept also prevented radiographic progression; mean change in Genant-modified Sharp score, from baseline to one year, was 0.01 in abatacept-treated patients vs 1.11 in placebo controls (95% confidence interval for difference between the groups: $-2.05$ to $-0.15$).

### B cell inhibition: rituximab

Rituximab is a human-mouse chimeric monoclonal antibody that selectively depletes CD20-expressing B cells. The mechanism by which rituximab depletes B cells may be by cell-mediated or complement-dependant toxicity, or by promotion of apoptosis.\textsuperscript{53} It has been used to treat non-Hodgkins lymphoma since 1997, but has since been licensed for use in RA in combination with MTX.\textsuperscript{54} It is administered in two intravenous infusions of 1g, two weeks apart, with intravenous glucocorticoid. Usually, a clinical response is seen at 16 weeks and lasts at least 6 months, after which treatment can be repeated. Usually, response to re-treatment is similar to the initial response.\textsuperscript{55} Response has been shown to be related to the level of B cell depletion in the blood after the first infusion; at 12 months, 59% of patients with complete depletion of B cells (below $0.0001 \times 10^6$ liter) still had a moderate to good clinical response, compared to 21% of patients with partial depletion.\textsuperscript{56} Vital et al demonstrated that patients who were not clinically responding to rituximab at 6 months had higher B cell concentrations prior to treatment than responders, and were less likely to achieve complete depletion after the first infusion.\textsuperscript{57} When these nonresponders were re-treated with rituximab after 6 months 72% achieved a clinical response.

An initial open-label phase IIa study by Edwards et al assessed clinical response when rituximab was used alone and in combination with MTX or cyclophosphamide, compared to MTX alone.\textsuperscript{58} Cyclophosphamide (750 mg on days 3 and 17) was used due to prior success of rituximab in treatment of lymphoma in the CHOP regimen (cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone). At 24 and 48 weeks, greater numbers of patients achieved ACR20 responses in all rituximab groups compared to MTX alone, but the difference was only significant for rituximab in combination with MTX (Table 9). The percentage of patients achieving a meaningful improvement in HAQ DI (decrease of $\geq 0.22$ from baseline) was greatest in the rituximab-MTX

### Table 9

<table>
<thead>
<tr>
<th></th>
<th>Edwards et al\textsuperscript{58}</th>
<th>DANCER\textsuperscript{59}</th>
<th>REFLEX\textsuperscript{60}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MTX n = 40</td>
<td>MTX + rituximab n = 41</td>
<td>MTX + placebo n = 121</td>
</tr>
<tr>
<td></td>
<td>Rituximab n = 40</td>
<td>MTX + rituximab n = 40</td>
<td>MTX + rituximab n = 115</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MTX + placebo n = 209</td>
<td>MTX + rituximab n = 311</td>
</tr>
<tr>
<td><strong>At 24 wks (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td>38</td>
<td>28</td>
<td>18</td>
</tr>
<tr>
<td>ACR 50</td>
<td>13</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>ACR 70</td>
<td>5</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td><strong>At 48 wks (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td>20</td>
<td>49</td>
<td>65\textsuperscript{a}</td>
</tr>
<tr>
<td>ACR 50</td>
<td>5</td>
<td>27</td>
<td>35</td>
</tr>
<tr>
<td>ACR 70</td>
<td>0</td>
<td>10</td>
<td>15</td>
</tr>
</tbody>
</table>

\textbf{Note:} \textsuperscript{a} $P < 0.001$ compared to placebo group.

\textbf{Abbreviations:} ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; CYC, cyclophosphamide; MTX, methotrexate.
group (68% vs 39% and 43% in other rituximab groups and 28% in the MTX monotherapy group). Follow-up was continued two years after rituximab treatment. In this time, a number of patients discontinued from the study due to lack of efficacy or relapse, and received alternative therapy or retreatment with rituximab. At two years, 45% of patients in the rituximab-MTX group had not required further treatment, compared to 22% in the rituximab plus cyclophosphamide group, 10% in the rituximab monotherapy group, and 15% in the MTX-only group.

The DANCER trial investigated differing doses of rituximab with MTX, with or without glucocorticoids, in patients with active RA despite at least three months of MTX treatment. Beyond 4 weeks, clinical response was not significantly affected by glucocorticoid treatment, but ameliorated acute infusion reactions. Therefore, results were pooled according to rituximab dose. When results for rheumatoid factor-negative patients were analyzed (85 out of 465 patients), rituximab showed no superior efficacy over placebo (48% achieved ACR20 at 24 weeks compared to 52% of controls), and their results were excluded from the main analysis (Table 9). The proportion of patients who had a meaningful decrease in HAQ DI (≥0.22 from baseline) was 67% with rituximab, compared to 34% in controls.

Patients enrolled in the REFLEX trial had active RA despite three months of MTX treatment, and had failed previous anti-TNF treatment, either due to lack of efficacy (90% of patients) or intolerance. Rituximab had a significant effect on HAQ DI (mean improvement of 0.4 compared to 0.1 in controls; \( P < 0.0001 \)), and on quality of life (mean improvement in PCS was 5.8 vs 0.9, and MCS was 4.7 vs 1.3; \( P = 0.0002 \) for both scores). The effect of rituximab on radiographic progression was assessed by comparing Genant-modified Sharp scores at week 24 to baseline. A trend was seen towards reduction of radiographic progression. However, results did not reach statistical significance; mean change in total score in the rituximab group was 0.6 compared to 1.2 in controls (\( P = 0.169 \)).

### II-6 inhibition: tocilizumab

Amongst its many roles, II-6 is involved in differentiation of B cells into plasma cells, and activation of T cells. Tocilizumab is an antibody against the II-6 receptor, inhibiting II-6 binding, and is produced from human immunoglobulin and mouse antibody to the human II-6 receptor by recombinant DNA technology. It is administered intravenously every 4 weeks.

Tocilizumab was used alone and in combination with MTX in the CHARISMA trial, in patients with an inadequate response to MTX. The study showed the greatest number of patients who achieved the primary endpoint (ACR20 at 20 weeks) were those treated with tocilizumab 8 mg/kg plus MTX (74% compared to 41% in the placebo plus MTX group; \( P = 0.001 \)). This is the dose used in clinical practice. Response with tocilizumab 8 mg/kg monotherapy was less impressive (Table 10).

Further evidence of efficacy of tocilizumab in combination with MTX or other DMARDs is available (Table 10). The OPTION study included patients with an inadequate response to MTX. A small number had received previous anti-TNF treatment (51 patients; 8%). The TOWARD study assessed the combination of tocilizumab with other conventional DMARDs in patients with active RA despite eight weeks of treatment with DMARD therapy. Approximately 75% of patients were receiving MTX as the concomitant DMARD. Improved quality of life was seen in tocilizumab groups in both studies, with statistically significant differences between mean improvements from baseline in MCS and PCS scores (\( P \leq 0.001 \)).

### Table 10 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with tocilizumab monotherapy and in combination with methotrexate or DMARD. Tocilizumab groups received 8 mg/kg every 4 weeks

<table>
<thead>
<tr>
<th></th>
<th>CHARISMA63</th>
<th>OPTION64</th>
<th>TOWARD65</th>
<th>RADIATE66</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MTX +</td>
<td>TCZ</td>
<td>MTX +</td>
<td>TCZ</td>
</tr>
<tr>
<td></td>
<td>placebo</td>
<td>n</td>
<td>placebo</td>
<td>n</td>
</tr>
<tr>
<td>n</td>
<td>49</td>
<td>52</td>
<td>50</td>
<td>204</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20–24 wks (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20</td>
<td>41</td>
<td>63</td>
<td>74†</td>
<td>26</td>
</tr>
<tr>
<td>ACR 50</td>
<td>29</td>
<td>41</td>
<td>53</td>
<td>11</td>
</tr>
<tr>
<td>ACR 70</td>
<td>16</td>
<td>16</td>
<td>37</td>
<td>2</td>
</tr>
</tbody>
</table>

Note: \( P < 0.001 \) compared to placebo.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; TCZ, tocilizumab.
RADIATE was a trial in RA patients who had received one or more anti-TNF therapies in the previous year but had failed treatment due to lack of efficacy or intolerance (approximately half of patients had failed more than one anti-TNF). The results are similar to those seen with rituximab subsequent to failed anti-TNF in the REFLEX study, with half of patients achieving an ACR20 response, compared to 10% of patients on MTX alone.

Affect on radiographic progression was assessed in the SAMURAI and LITHE studies. In the SAMURAI study, patients with an inadequate response to DMARD therapy were randomized to tocilizumab monotherapy or continuing conventional DMARD treatment. At one year, the tocilizumab group showed less radiographic progression, with a mean change in total Sharp score of 2.3 compared to 6.1 in the DMARD group (P < 0.01). The LITHE study was a double-blind randomized controlled trial of tocilizumab combined with MTX, compared to MTX monotherapy, in MTX nonresponders. Again, the tocilizumab group showed less progression, with mean change in total Genant-modified Sharp score of 1.3 compared to 3.0 (P < 0.0001).

In MTX-naïve patients, the AMBITION study compared efficacy of tocilizumab monotherapy to MTX. A significantly higher proportion of patients receiving tocilizumab achieved ACR20 response at 24 weeks (70% compared to 53%; P < 0.0001), and one third of patients achieved DAS28 remission, compared to 12% of patients receiving MTX.

For the purpose of analyzing long-term efficacy, patients from these randomized controlled trials (OPTION, TOWARD, RADIATE, LITHE, and AMBITION) were enrolled in long-term extension studies, in which all patients receive tocilizumab for up to five years, and are currently ongoing. Interim results at 2.5 years have been published, showing continued improvement of ACR responses over time, and only 3% withdrawal rate due to lack of efficacy.

**Tolerability**

In trials, rates of adverse events with anti-TNF treatments, and discontinuation rates due to adverse events, are generally comparable to rates seen in control groups. For example, the ATTRACT study demonstrated that adverse events were as common in all infliximab groups as in the placebo group. An adverse event was reported at least once in 80% of patients. However, these were well-tolerated, causing the discontinuation of treatment in 3%–7% of patients across infliximab treatment groups, which compared to 8% in the placebo group. Infusion reactions were more common with infliximab (16%–20% compared to 10% in the placebo group), but were usually mild and transient. In the STAR study (Safety Trial of Adalimumab in Rheumatoid Arthritis), patients were randomized to adalimumab or placebo, and continued on their conventional DMARDs. There was no significant difference in total adverse event rates (87% with adalimumab vs 83% with placebo), and when the type of event was considered, a significant difference between groups was only seen in injection site reactions (20% vs 12%), rash (11% vs 6%), and back pain (5% vs 3%). The TEMPO trial of etanercept as monotherapy and in combination with MTX reported similar total adverse event rates (81% and 86% respectively, compared to 81% with MTX monotherapy). In terms of type of event, a significant increased incidence with etanercept was only seen in injection site reactions.

Certolizumab and golimumab have been shown to differ from other anti-TNF therapies in that rate of injection site reactions are not increased compared to controls. In the FAST4WARD study, the rate of injection site reactions was 5% with certolizumab compared to 14% with placebo. In GO-FORWARD the rate was 2% with golimumab compared to 3% in controls.

Trials have shown tolerability of abatacept is similar to anti-TNF treatment in RA. For example, the total adverse event rates in the AIM study were 87% with abatacept compared to 84% with placebo. The longest running open-label extension trial of abatacept treatment, by Kremer et al reported a 17% discontinuation rate due to adverse events over 5 years.

With rituximab, the most frequent adverse events are infusion reactions. These are reduced by premedication with intravenous glucocorticoid, but remain common with the first infusion of each course; acute infusion reaction occurred in 29% of patients treated with two doses of 1000 mg rituximab in the DANCER study, and 23% of patients in the REFLEX study. The rate decreases for the second infusion (approximately 10%). Total adverse events occurred in 85% of patients receiving two doses of 1000 mg rituximab in both DANCER and REFEX trials (compared to rates of 70% and 88% in placebo groups). They were largely well-tolerated; adverse events led to withdrawal of treatment in 3% of patients in both trials.

In the largest randomized controlled trial of tocilizumab (the TOWARD study of 1,220 patients), the incidence of adverse events was higher in the tocilizumab group compared to controls (73% compared to 61%). The majority of events though were mild to moderate in severity and generally tolerated; the discontinuation rate due to adverse events was 4%, compared to 2% for controls.
Safety of biologics

There are important safety issues with the use of biologic therapy, not least because their targets in the immune system have a role in the body’s defence against infection and malignancy. Difficulties arise in assessing their safety, as any increase in rates of malignancy and infection (both of which are associated with RA) may reflect greater disease severity and not biologic treatment. Evidence of their safety is available from registries of patients receiving biologics; for example, the British Society for Rheumatology Biologics Register (BSRBR). This includes a control group of 3,106 RA patients treated with DMARDs, but these patients are likely to have less severe disease if they have not required biologic therapy. Randomized controlled trials are generally not powered to detect rare adverse effects such as malignancy. Meta-analyses of trials may go a way towards solving this issue. However, it is important to note that trials may exclude patients with co-morbidities, and therefore their results may not apply to the general RA population.

Infection

There is an increased risk of infection with biologic therapy, and they are contraindicated in the presence of active, severe infection. Risk of serious infection (infection requiring intravenous antibiotics, or leading to hospitalization or death) with biologic treatment is summarized in Table 11.

There is an increased risk of tuberculosis (TB), either reactivation of latent infection or increased susceptibility to infection. It can present atypically, for example, as extra-pulmonary or miliary TB. Out of the 10,403 patients on anti-TNF therapy in the BSRBR, there have been 35 cases of TB, with no cases in the DMARD group.76

Trials excluded patients with active TB or latent TB on anti-TNF treatment. There is a difference in risk within the group of anti-TNFs. Adalimumab and infliximab (the monoclonal antibodies) are associated with higher rates compared to the receptor fusion protein etanercept. This may be due to differences in their mechanism of action. The monoclonal antibodies also inhibit T cell activation and the production of interferon gamma, whereas the function of interferon gamma is preserved with etanercept treatment.77 All patients should be screened for latent infection prior to receiving anti-TNF. The optimal treatment for latent TB prior to commencing anti-TNF treatment has not been investigated in trials. Observational data, for example, from the Spanish biologics registry, reports that screening for TB and treatment with isoniazid prior to anti-TNF therapy significantly decreases the risk, but does not eliminate it.78 There is no evidence that rituximab increases the risk of TB in clinical trials. Trials excluded patients with active TB or latent TB on chest X-ray, but have not screened for latent TB by purified protein derivative testing.

Anti-TNF treatments are contraindicated in chronic hepatitis B infection, as infliximab has been associated with viral reactivation in a number of case reports.79 Etanercept is considered to be safe in hepatitis C. A prospective study of eight patients and a randomized controlled trial have shown no increase in viral load or adverse events with etanercept.80,81 Hepatitis B reactivation has been reported after rituximab treatment in lymphoma patients, but successful treatment with prophylaxis has been possible. RA trials have screened for hepatitis B and C.

Table 11 Risk of serious infection with biologic treatment

<table>
<thead>
<tr>
<th>Biologic agent</th>
<th>Risk of serious infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-TNF</td>
<td>A meta-analysis of trials of infliximab and adalimumab calculated the risk was approximately double that with conventional DMARD treatment (odds ratio 2.0; 95% confidence interval: 1.3 to 3.1).72</td>
</tr>
<tr>
<td></td>
<td>A retrospective observational study of over 700 patients on anti-TNF compared the incidence of serious infections on treatment to the incidence in the same patients prior to treatment.73 Rates of serious infection in the first year were 10 per 100 patient years compared to 3 per 100 patient years prior to anti-TNF treatment.</td>
</tr>
<tr>
<td></td>
<td>The rate of serious infection from BSRBR data was 6 per 100 patient years.74 When adjustment was made for confounding factors such as co-morbidities, this was not significantly different from the rate in patients on conventional DMARDs. However, when the incidence rate over the first 90 days of anti-TNF treatment was calculated, a four-fold increase in serious infections was seen in this initial period of treatment.</td>
</tr>
<tr>
<td>Abatacept</td>
<td>In the open-label extension trials discussed previously, the rate of serious infections was 3–5 per 100 patient years across the studies.47–49</td>
</tr>
<tr>
<td>Rituximab</td>
<td>In the DANCeR and REFLeX trials, incidence of serious infection was 5 per 100 patient years in both trials (compared to rates of 3–4 per 100 patient years in control groups).33,46 Long-term safety data with repeated treatments has shown similar rates of serious infection for each cycle of treatment.75</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>In the TOWARD study, the rate of serious infection was 6 per 100 patient years, compared to 5 per 100 patient years with DMARD therapy alone.85</td>
</tr>
</tbody>
</table>

Abbreviation: BSRBR, British Society for Rheumatology Biologics Register.
for hepatitis B and C prior to treatment. Therefore, screening for hepatitis B and C is recommended.54

There are case reports of fungal infections with anti-TNF therapy, for example, histoplasmosis or aspergillosis, although the incidence is extremely low.79

Malignancy
There is concern that anti-TNF and abatacept therapies may put patients at risk of malignancy due to the role of TNF and T cells in cancer immunosurveillance.

A meta-analysis of adalimumab and infliximab trials has shown increased rates of malignancy compared to placebo or placebo plus DMARD (pooled odds ratio 3.3; 95% confidence interval: 1.2 to 9.1). However, these trials included high doses of infliximab (6 mg/kg every eight weeks or more).72 Observational studies indicate that anti-TNF therapy is associated with an increased risk of nonmelanotic skin cancers but not solid tumor malignancies. For example, a study of approximately 3,000 patients treated with anti-TNF in the United States of America reported an incidence rate of nonmelanotic skin cancer of 26 per 1,000 patient years, compared to 20 per 1,000 patient years in patients treated with conventional DMARDs.82 A Swedish study reported a standardized incidence rate of solid tumors of 0.9 in 4,000 RA patients on anti-TNF, which compared to the standard incidence rate of 1.05 in over 50,000 RA patients.83 However, anti-TNF may have been avoided in patients at risk of malignancy, or with a previous history of malignancy, because of a theoretical risk. Data available from the BSRBR, of patients with a history of previous malignancy, does not demonstrate any increased cancer risk with anti-TNF.84

Anti-TNF treatment is contraindicated in patients with a history of a lymphoproliferative disorder within the last five years. There have been reports of higher incidence rates of lymphoma in patients on anti-TNF therapies in comparison to rates seen in the general RA population; for example, the French RATIO registry data.85 In other cohort studies however, such as the Swedish cohort described above, no increase in incidence has been seen.86

With abatacept, a total of 42 malignancies were seen in the 1,167 patients who were exposed to at least one dose of abatacept in the open-label extension studies discussed previously.47–49 The commonest types were nonmelanotic skin cancers (21 cases), pulmonary malignancy (6 cases), and lymphoma (3 cases). This incidence of pulmonary neoplasm and lymphoma is similar to that in the RA population.

Anaphylaxis
Infliximab has a higher propensity than other anti-TNF therapies to cause anaphylaxis, as it is a chimeric molecule, but maybe also because it is administered intravenously. In the START study (Safety Trial for Rheumatoid Arthritis with Remicade Therapy), 5 out of 1,442 patients treated with infliximab developed serious infusion reactions.87

Rituximab, another chimeric molecule, is contraindicated in patients who have had a hypersensitivity reaction to infliximab. In the REFLEX study, only two infusion reactions out of 308 rituximab-treated patients were reported as severe, one reaction being anaphylaxis, the other hypertension.60

Autoimmune syndromes and psoriasis
Anti-TNF therapy is associated with the production of autoantibodies (antinuclear antibodies and double-stranded DNA antibodies). Rarely, anti-TNF can cause autoimmune hepatitis, vasculitis, and drug-induced systemic lupus erythematosus (occurring in approximately 0.2% of patients).79 These conditions generally improve with drug withdrawal. There are also reports of new-onset of skin psoriasis and worsening of existing psoriasis on anti-TNF therapy. There have been 25 new cases of psoriasis in patients on anti-TNF treatment in the BSRBR, equivalent to an incident rate of 1.04 per 1,000 patient years, compared to no cases in patients on conventional DMARDs.88

Autoimmune syndromes have also been seen with abatacept. The extension studies reported vasculitis in 9 patients.47–49 Other, rarer events were sicca syndrome (3 patients), erythema nodosum (2 patients), multiple sclerosis, systemic lupus erythematosus, and sjögren's syndrome (1 patient each). There were 16 new cases of psoriasis.

Neurological
Anti-TNF is contraindicated in patients with a history of Parkinson's disease or demyelinating conditions such as optic neuritis or multiple sclerosis, and treatment should be stopped if these disorders occur on treatment. Case reports of development of demyelinating disorders on anti-TNF therapy have been published.79 The role of anti-TNF therapy in their causality is impossible to prove, but is suggested by the fact that they generally improve, at least partially, on drug withdrawal.

After treatment with rituximab, the very rare but usually fatal condition of progressive multifocal leukoencephalopathy has been seen. A review of cases from post-marketing surveillance and published literature up until December 2008.
revealed 57 cases.89 Cases were in patients with known risk factors for the disease, including lymphoma and treatment with additional potent immunosuppressants. This included one patient with RA who had previously received chemotherapy for oral malignancy.

Hematological
Pancytopenia and aplastic anemia while on anti-TNF therapy have been reported. Again, it is difficult to conclude that this is caused by anti-TNF treatment, as these cases are extremely rare,79 but if these conditions develop, anti-TNF treatment should be stopped.

Neutropenia is a complication of tocilizumab treatment. In the TOWARD study, 29% of patients in the tocilizumab group had neutrophil levels below the normal range, compared to 4% of patients in the control group.65 Importantly, neutropenia was not associated with any infection-related adverse events. Only 4% had severe neutropenia (neutrophils less than 500 per mm$^3$).

Cardiovascular
Patients with rheumatoid arthritis have a higher incidence of cardiovascular disease than the general population, with a cardiovascular mortality rate of approximately 1.5 times higher than the general population.2 Raised levels of inflammatory markers and cytokines are associated with increased risk of cardiovascular disease, and research has shown levels of TNF are increased in congestive heart failure. On this basis, randomized controlled trials of etanercept in congestive heart failure were conducted, but were terminated early due to higher mortality rates with etanercept treatment.90 There are also reports of new-onset congestive heart failure and worsening of existing heart failure with anti-TNF therapy (without other identifiable risks or precipitating factors). Anti-TNF therapy is therefore contraindicated in moderate to severe heart failure (New York Heart Association class III or IV). Rituximab is also contraindicated in severe heart failure (New York Heart Association class IV), but data is not available in patients with heart failure in classes I to III.70

Tocilizumab, by suppressing the effect of IL-6 on the liver, is associated with increased lipid levels (which are suppressed by inflammation). For example, the TOWARD study revealed low-density lipoprotein cholesterol increased to over 160 mg/dl in 16% of patients, compared to 3% of controls.65 Levels improve with lipid-lowering therapy. However, the implication for long-term cardiovascular safety is uncertain.

Pregnancy
There is a lack of evidence for the safety of biologic therapy in pregnancy and lactation. There is data available for 32 pregnancies in the BSRBR.91 Twenty three women were receiving anti-TNF therapy at the time of conception, and the majority (21 women) discontinued anti-TNF during the first trimester. Of these 23 pregnancies, first trimester miscarriage occurred in 6, elective miscarriage in 3, and out of 14 live births there were no congenital malformations. Three of the women who spontaneously miscarried were also taking MTX, which makes this data difficult to interpret.

Discussion
Rheumatoid disease, being a chronic condition, requires drug treatments that are effective, well-tolerated, and safe over the long term. Although it is generally not immediately life-threatening, it can lead to significant disability, job loss, and systemic complications such as cardiovascular disease. Benefits need to be balanced against potential risks of biologic treatments.

Patients and physicians need to be aware of the risks with biologic treatment, which include an increased risk of infection (all biologics), development of autoimmunity (anti-TNF therapy and abatacept), and deterioration of heart failure (anti-TNF and possibly rituximab). Prior to treatment, patients should be fully assessed for potential risks. Screening for TB and hepatitis is recommended due to the risk of reactivation with anti-TNF. The potential increased risk of lymphoma with anti-TNF treatment remains unclear. A history of a lymphoproliferative disease within the last five years remains a contraindication to anti-TNF. Although adverse event rates with biologic treatment are high in randomized studies, they are generally comparable to rates with conventional DMARDs. The exception to this is infusion or injection site reactions. However, these are mostly well-tolerated and decrease over time, only infrequently leading to drug discontinuation.

Biologic therapies are available for patients with RA who are resistant to conventional DMARDs. Trials have demonstrated the efficacy of biologics over conventional DMARDs in these circumstances, with greater proportions of patients achieving ACR20 responses. For example, one of the earliest trials, the ATTRACT study, showed that patients were twice as likely to achieve an ACR20 response at one year with infliximab and MTX treatment compared to MTX alone.12 This holds clinical meaning for patients. An ACR20 is a composite endpoint that includes
improvement in the number of swollen and tender joints, but also the individual patient’s assessment of their pain, health, and physical functioning. Trials have also reported the proportion of patients achieving meaningful improvement in physical functioning and health-related quality of life. This perhaps carries more meaning for patients than do reports of the average improvement in scores, which could be affected by a dramatic improvement in a small minority of patients. It should be noted that the majority of studies discussed in this review are of patients with active arthritis with high tender and swollen joint counts at enrolment. In clinical practice, patients often have lower tender and swollen joint counts. Therefore, the responses seen in the trials discussed here may not be directly applicable to a number of patients.

Several anti-TNF drugs have been developed, with different methods of administration but similar efficacy. A range of available anti-TNF therapies has been important for clinical practice, as some patients develop side-effects specific to certain drugs, and others may not respond or may lose their initial response to therapy. In the latter, there is observational evidence that switching to alternative anti-TNF is successful. In the case of golimumab, there is evidence from a randomized controlled trial. Other classes of biologics have proved necessary because, in a proportion of patients, anti-TNF is ineffective or is contraindicated; for example, in patients with malignancy. Evidence for the use of the other classes of biologics in anti-TNF nonresponders is available from clinical trials of abatacept, rituximab, and tocilizumab. Approximately half of patients on these treatments were achieving ACR20 responses at 6 months, which is striking, considering these were patients with disease that had been difficult to treat.

Efficacy of biologic treatments has been assessed in patients recently diagnosed with RA who have not yet failed conventional treatments such as MTX. These studies have shown that a greater proportion of patients achieve the higher levels of improvement (ACR50 and ACR70 responses), and higher rates of clinical remission, with biologics compared to conventional DMARDs. For example, the COMET study showed that patients were nearly twice as likely to achieve remission with etanercept and MTX compared to MTX alone after one year (remission rates of 50% compared to 28%). Improved rates of remission in the early stages of disease may have important consequences for the future in these individuals. For instance, as onset of rheumatoid disease occurs most commonly in middle age, any disruption of a person’s ability to work at this stage could have implications for their later career. It may also be important in preventing early joint damage, which is more rapid in the early stages of the disease, and so limit future disability from structural deformities. Both of these aspects of efficacy of early biologic treatment have been demonstrated; for example, reduction in job loss (in the PROWD study) and prevention of structural damage (in the COMET study).

It has been suggested that early biologic treatment may arrest the disease if used early in its course, and that long-term remission after cessation of biologic treatment may be achievable. For example, drug withdrawal was most successful in the infliximab arm of the BeSt study; sustained remission one year after withdrawal of infliximab was achieved by Quinn et al in very early RA; and reduction in rate of progression of undifferentiated arthritis to RA has been seen six months after withdrawal of abatacept. As discussed above, biologic therapies are not without any safety concerns and are financially costly. Therefore, it has been proposed that if biologic therapies were available as first-line treatments in clinical practice, patients should be selected, perhaps by predictors of poor prognosis. Initial financial cost may be offset if biologic therapy enables more young people to stay in work, reducing long-term healthcare costs by preventing later disability and other consequences of RA such as cardiovascular disease, and especially if drug-free remission can be attained.

Disclosure
The authors report no conflicts of interest in this work.

References


